Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Other
  • Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026
  • Other

Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026

BioPharma Dive

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what s been observed over a similar timeframe in prior years, according to

OtherRead full story

pharminent March 31, 2026 (Last updated: March 31, 2026)

BioPharma Dive

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what s been observed over a similar timeframe in prior years, according to

OtherRead full story

Post navigation

Previous: AZ considers filings for long-acting Strensiq follow-up
Next: Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo

Related Stories

  • Other

Takeda and Weave Bio collaborate on AI-driven automation in drug development

pharminent September 2, 2026
  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

pharminent June 2, 2026
  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.